Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?

Dermatol Ther. 2019 Jan;32(1):e12780. doi: 10.1111/dth.12780. Epub 2018 Nov 28.

Abstract

Compounded topical preparations (CTP) were used to treat psoriasis until the last century and have disappeared from guidelines. The present authors report two severe psoriasis patients who were treated with CTP. A man had psoriasis with a PASI of 23 and a body surface area (BSA) of 43%. He had been using daily for several weeks a CTP including minoxidil, clobetasol propionate and hydroxyprogesterone formulated in an alcohol based vehicle. A woman suffered from psoriasis with an annular inflammatory pattern and a central healing. The PASI was 20 and the BSA was 30%. She had been using a CTP daily for 4 months including resorcinol, salicylic acid, 0.05% tretinoin cream, bethamethasone dipropionate cream. Until the 1970s, the dermatological textbooks recommended to treat severe psoriasis with CTP. Nowadays, CTP are considered outdated because of the large therapeutic armamentarium. The stability and benefit risks of the CTP used here were not documented. The use of CTP in psoriasis should be regulated and must be evidence based. Strict protocol and stability evaluation for preparations must be confirmed prior to compounding.

Keywords: compounded topical formulations; psoriasis; therapeutic.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Chronic Disease
  • Cyclosporine / administration & dosage*
  • Cyclosporine / adverse effects
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / chemistry
  • Drug Compounding*
  • Drug Substitution
  • Female
  • Humans
  • Male
  • Methotrexate / administration & dosage*
  • Methotrexate / adverse effects
  • Middle Aged
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Remission Induction
  • Skin / drug effects*
  • Skin / pathology
  • Time Factors
  • Treatment Outcome

Substances

  • Dermatologic Agents
  • Cyclosporine
  • Methotrexate